Symbols / VIGL
VIGL Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 07:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? - Yahoo Finance Mon, 02 Jun 2025 07
- Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi - Investopedia hu, 22 May 2025 07
- Sanofi's $600M Acquisition Targets Novel Alzheimer's Treatment: Inside the Vigil Neuroscience Deal - Stock Titan Wed, 21 May 2025 07
- VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - PR Newswire Wed, 04 Jun 2025 07
- Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline - Reuters hu, 22 May 2025 07
- Sanofi Buys Vigil for $470M Upfront, Reigniting a Battered Alzheimer’s Target - BioSpace hu, 22 May 2025 07
- Vigil takeover brings TREM2 Alzheimer’s prospect to Sanofi - BioWorld MedTech hu, 22 May 2025 07
- Sanofi completes acquisition of Vigil Neuroscience and initiates delisting from Nasdaq - Investing.com UK ue, 05 Aug 2025 07
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share - Yahoo Finance hu, 22 May 2025 07
- Vigil Neuroscience Reports Q1 2025 Financial Results and Updates on Clinical Trials for Iluzanebart and VG-3927 - Nasdaq Wed, 07 May 2025 07
- Vigil Neuroscience: Down On A Competitor's Failure (NASDAQ:VIGL) - Seeking Alpha ue, 03 Dec 2024 08
- Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More - Yahoo Finance Fri, 23 May 2025 07
- Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi - Stock Titan hu, 27 Jun 2024 07
- VIGL - Vigil Neuroscience, Inc. Latest Stock News & Market Updates - Stock Titan Sat, 08 Jan 2022 23
- Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Yahoo Finance Sat, 01 Mar 2025 08
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for VIGL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|